Journal of Nanobiotechnology (May 2022)

Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations

  • Ruslan G. Tuguntaev,
  • Abid Hussain,
  • Chenxing Fu,
  • Haoting Chen,
  • Ying Tao,
  • Yan Huang,
  • Lu Liu,
  • Xing-Jie Liang,
  • Weisheng Guo

DOI
https://doi.org/10.1186/s12951-022-01451-4
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 31

Abstract

Read online

Abstract Nanomedicines (NMs) have emerged as an efficient approach for developing novel treatment strategies against a variety of diseases. Over the past few decades, NM formulations have received great attention, and a large number of studies have been performed in this field. Despite this, only about 60 nano-formulations have received industrial acceptance and are currently available for clinical use. Their in vivo pharmaceutical behavior is considered one of the main challenges and hurdles for the effective clinical translation of NMs, because it is difficult to monitor the pharmaceutic fate of NMs in the biological environment using conventional pharmaceutical evaluations. In this context, non-invasive imaging modalities offer attractive solutions, providing the direct monitoring and quantification of the pharmacokinetic and pharmacodynamic behavior of labeled NMs in a real-time manner. Imaging evaluations have great potential for revealing the relationship between the physicochemical properties of NMs and their pharmaceutical profiles in living subjects. In this review, we introduced imaging techniques that can be used for in vivo NM evaluations. We also provided an overview of various studies on the influence of key parameters on the in vivo pharmaceutical behavior of NMs that had been visualized in a non-invasive and real-time manner. Graphical Abstract

Keywords